ImmunoGenomics

What ImmunoGenomics does

ImmunoGenomics is a CLIA-certified precision medicine laboratory headquartered in Sugar Land, Texas, operating as a private for-profit entity founded in 2020 with 11–50 employees. The company delivers a broad molecular and genetic diagnostics menu across five core verticals: pharmacogenomics (PGx) via a 21-gene panel covering CYP and other drug-metabolizing enzymes, nutrigenomics (NGx), toxicology screening and GC-MS/LC-MS confirmation, infectious disease molecular panels (respiratory, STI, COVID-19, GI, UTI, wound), and inherited disease panels (cardiac, eye, immunodeficiency). Underlying technology is PCR and molecular amplification-based testing, with sample collection supported by an in-house lab, mobile phlebotomy, and at-home cheek-swab kits returned via FedEx.

The business model combines per-test lab fees billed to providers and patients, insurance reimbursement under contracts with Medicare, Medicaid, Blue Cross Blue Shield of Texas, and Novitas, and direct-to-consumer self-pay (e.g., PGx at $300, COVID PCR at $230, antigen at $75). GTM is hybrid: sales-led to healthcare providers through online forms, downloadable requisitions, and the GenXys provider portal; and direct-to-consumer via website booking, the PreciseQ patient portal, and a Shopify-based affiliate storefront. The company is licensed to operate in Texas, New York, and California, and markets to hospitals, skilled nursing facilities, community mental health centers, rural health clinics, and individual patients seeking personalized medication, nutrition, and infectious-disease testing.

Name

ImmunoGenomics

Legal name

ImmunoGenomics

Website

https://immunogeno.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

ImmunoGenomics is a CLIA-certified precision medicine laboratory in Sugar Land, Texas, offering pharmacogenomics, nutrigenomics, toxicology, infectious disease, and inherited disease molecular testing to providers, payers, and self-pay patients across Texas, New York, and California.

Ownership category

akta.pro rank

Product category

Clinical Laboratory Services

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Reference & Esoteric Testing Laboratories (HLAFAMAJ)

akta.pro secondary industries

Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

Keywords

• Molecular diagnostics
• Pharmacogenomics testing
• Infectious disease testing
• Toxicology screening
• Nutrigenomics testing

Headquarters

HQ city

Sugar Land

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Laboratory Testing Services: Per-test laboratory testing services for pharmacogenomics, nutrigenomics, toxicology, infectious diseases, and molecular diagnostics. Tests are ordered by healthcare providers or directly by patients and billed per test.
2. Insurance Reimbursement: Revenue from insurance payers including Medicare, Medicaid, Blue Cross Blue Shield of Texas, and Novitas. The company accepts various insurance plans and bills insurance for covered tests.
3. Self-Pay Testing: Direct-to-consumer testing at affordable prices for patients without insurance coverage or provider orders. PGx testing available for $300 without medical necessity for preventive approach.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

ImmunoGenomics is a CLIA-certified precision medicine molecular diagnostic laboratory that performs clinical laboratory testing services covering pharmacogenomics (PGx), nutrigenomics (NGx), infectious disease panels, toxicology screening and confirmation, COVID-19 testing, and routine blood work. Tests are ordered by healthcare providers via the GenXys provider portal or downloadable requisitions, or directly by patients through the website booking calendar and at-home specimen collection kits returned via FedEx.

Product overview

ImmunoGenomics is a CLIA-certified precision genomics laboratory offering a multi-product portfolio of genetic and molecular diagnostic testing services. The core offerings include Pharmacogenomics (PGx) for medication response prediction, NutriGenomics (NGx) for personalized nutrition, Molecular Testing Panels covering infectious diseases (respiratory, UTI, STI), inherited conditions (cardiac, eye, immunodeficiency), and toxicology screening/confirmation services. The company provides both healthcare provider-ordered testing and at-home specimen collection kits, operating as a single laboratory platform with multiple specialized testing divisions. Additional services include routine lab testing, cancer genomics, and mobile phlebotomy. The laboratory is licensed in Texas, New York, and California, with insurance contracts including Novitas, California's Medicaid, and Blue Cross Blue Shield of Texas.

Differentiator

Problem solved

Functional benefit

Brands

• IGIteration: Brand name appearing in website footer

Products and services

• Pharmacogenomics (PGx) Testing Genetic testing service analyzing 21 genes (CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, and others) to predict medication response and guide drug selection and dosing for healthcare providers and patients.
• NutriGenomics (NGx) Genetic testing service that examines the relationship between genetics and nutrition to provide personalized dietary recommendations based on metabolism, nutrient absorption, food sensitivities, and optimal macronutrient ratios.
• Molecular Testing Panels Comprehensive molecular diagnostic panels using PCR and nucleic acid amplification techniques to detect respiratory pathogens, STIs, inherited cardiac/eye diseases, and immunodeficiency disorders.
• Toxicology Testing Drug testing services including both qualitative immunoassay-based screening and GC-MS/LC-MS-based definitive confirmation panels for prescription medications, illicit substances, and pharmaceutical metabolites.
• COVID-19 Testing Molecular diagnostic testing for SARS-CoV-2 including RT-PCR tests, rapid antigen tests, and saliva-based testing, with standard and expedited PCR options.
• Urinary Tract Infection (UTI) Panel Molecular diagnostic panel using multiplex testing technology to identify bacteria, viruses, and fungi causing urinary tract infections, with antibiotic resistance gene detection.
• Mobile Phlebotomy Services On-site blood and body fluid collection services reaching individuals, homebound patients, physicians, hospitals, skilled nursing facilities, mental health centers, and rural health clinics across various care settings.
• At-Home Testing Kits Home-based specimen collection service where patients receive a kit by mail, self-collect DNA samples via cheek swab, and return samples to the laboratory via prepaid FedEx envelope for analysis.
• Routine Lab Testing Comprehensive blood testing services including basic metabolic panels, lipid profiles, and other routine clinical laboratory tests to assess overall health and identify potential medical conditions.

Quantifiable outcome

• Decreased hospitalizations from drug-gene interactions
• +2 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability1 record

Feature6 records

Partnerships

Four partnerships are on record, tiered core.

• NovitascoreOthersNovitas is a contracted insurance payer for ImmunoGenomics laboratory services. The company accepts Novitas insurance for covered testing services.
• California MedicaidcoreOthersImmunoGenomics accepts California's Medicaid program as an insurance payer for laboratory testing services.
• Blue Cross Blue Shield of TexascoreOthersBlue Cross Blue Shield of Texas is a contracted insurance provider for ImmunoGenomics laboratory testing services.
• GenXyscoreTechnology or IntegrationGenXys provides the provider portal technology used by ImmunoGenomics for healthcare provider ordering and real-time medication option integration. The portal enables providers to access PGx information for enhanced treatment decisions.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Genomind: Specialty PGx laboratory offering mental-health-focused pharmacogenomic testing to providers; directly comparable to ImmunoGenomics' psychiatry and pain management PGx products with similar provider-portal ordering model.
• InGenesis: Specialty clinical lab focused on pharmacogenomic and molecular testing with a multi-gene panel approach, overlapping directly with ImmunoGenomics' PGx and specialty molecular testing services.
• Molecular Testing Labs: Specialty molecular diagnostics lab with PGx, infectious disease, and DTC testing offerings; comparable in test menu, hybrid B2B/DTC model, and target customer segments.
• Dynamic DNA Labs: Specialty genetics lab offering pharmacogenomic, nutrigenomic, and molecular testing with both provider and direct-to-consumer ordering; highly comparable business model and test menu.
• Aegis Sciences Corporation: Clinical laboratory offering toxicology screening and confirmation testing plus PGx services to healthcare providers, including mental health and addiction treatment centers; overlaps with ImmunoGenomics' toxicology and PGx menus.

Broad incumbents

• Sonic Healthcare USA: International reference laboratory operator with US clinical lab footprint including specialty PGx and toxicology; competes broadly across ImmunoGenomics' test menu with deeper geographic coverage.
• Myriad Genetics: Established molecular diagnostics company with PGx (GeneSight) and hereditary disease testing; comparable in pharmacogenomic focus but with much greater commercial scale and clinical evidence base.
• Quest Diagnostics: Largest US clinical reference lab offering broad PGx, infectious disease, toxicology, and routine testing; competes with ImmunoGenomics on enterprise contracts and payer leverage but does not focus on specialty PGx.
• Laboratory Corporation of America (LabCorp): National clinical reference lab with comprehensive PGx, molecular, and toxicology offerings; a dominant broad incumbent that ImmunoGenomics must differentiate against on service and turn-around time.

Emerging players

• Castle Biosciences: Specialty molecular diagnostics company focused on inherited disease and oncology testing; comparable in offering specialty esoteric panels but operates in different end markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/Immunogeno
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/immunogenomicsdx
• Instagraminstagram.com/immunogeno.lab

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImmunoGenomics